fda warning about semaglutide WISH-TV - The has sent 30 letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2 FDA Drug Recalls and Warnings:

Earlier studies reported the influence of tamoxifen on cholesterol homeostasis and lipid metabolism of macrophages, supporting the beneficial consequences of this drug against foam cells formation and atherosclerosis (Figure 2

Together, they create not just slimmer bodies, but stronger, more confident women

Shes lifting heavier to protect muscle

52 thus began the competition between various GLP-1RAs

People who take the most common categories of weight-loss drugs, semaglutide and tirzepatide, marketed as Ozempic, Wegovy and Zepbound, tended to lose about 33 pounds during their treatment but then regained about 22 pounds in the first year after stopping, Sam West, a physiology researcher at Oxford University who co-wrote the study, said in a phone interview Thursday